Financials

Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

AZ's $80B revenue target 'very much within reach,' CFO says

Jan 14, 2026 10:00am

Upside for Insmed after Brinsupri’s first-in-class sales beat

Jan 9, 2026 10:40am

9 pharmas reach US drug price deals with Trump administration

Dec 19, 2025 3:35pm

UK cuts medicine rebate rate after US deal

Dec 10, 2025 1:00pm

Is Pfizer's recent ATTR sales decline in the US a warning sign?

Dec 2, 2025 8:20am